# 1 Title: Trends and factors associated with initiation of HIV treatment and

# 2 uptake of viral load testing among PLHIV in Jamaica

3 Anya Cushnie<sup>1</sup>¶\*, Ralf Reintjes<sup>1, 2</sup>¶, Miia Artama<sup>,1</sup>¶, J. Peter Figueroa<sup>3</sup>¶

| 4  |   |
|----|---|
| 5  | 1 Unit of Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland   |
| 6  | 2 Department of Health Sciences, Hamburg University of Applied Sciences, Hamburg, Germany:    |
| 7  | 3 Department of Community Health and Psychiatry, University of the West Indies, Mona, Jamaica |
| 8  |   |
| 9  | * Corresponding author: Anya Cushnie  |
| 10 | Email: anya.cushnie@gmail.com (AC)  |
| 11 |   |
| 12 | ¶ These authors contributed to this work.   |
| 13 |   |
| 14 |   |

15 (Word Count=3100)

## 17 Abstract:

Introduction: Jamaica did not achieve the UNAIDS 90-90-90 targets in 2020. This study aims to 18 examine trends and factors associated with uptake of HIV treatment and viral load testing among 19 people living with HIV (PLHIV) in Jamaica, to make recommendations for improving patient 20 21 management and outcomes. Methods: This secondary analysis uses patient-level data from the National Treatment Service Information System. The baseline sample is PLHIV initiating anti-22 retroviral treatment (ART) between January 2015-December 2019. Descriptive statistics are used 23 24 to summarize demographic and clinical variables. Multivariable logistic regression is used to assess factors associated with ART initiation (31+ days vs. same day) and viral load testing uptake 25 26 (viral load test vs. no test), using categorical variables for age group, gender and regional health 27 authority. Adjusted odds ratios and 95% confidence intervals are reported. Results: Same day ART initiation increased by 72% over 5 years. The coverage of 1<sup>st</sup> viral load test was 90% but 28 declined to 79% for the 2<sup>nd</sup> test. Testing occurred mostly after 0-6 months on ART (n=3047, 55%) 29 and uptake was highest in the South-East Region (n=2885, 53%). Those virally suppressed were 30 significantly more likely to have same day ART initiation compared to those non-suppressed 31 32 (aOR=1.58, CI=1.43-1.75). Males were significantly more likely to have same day ART initiation (aOR=1.46, CI=1.32-1.62) but no first viral load test (aOR=1.55, CI=1.27-1.90) compared to 33 females. Conclusion: The goal of immediate ART initiation is increasingly being met and is 34 35 significantly associated with viral suppression at the first viral load test. Males were less likely to have a viral load test after ART initiation. A qualitative assessment should be conducted to 36 understand important challenges faced to access routine viral load testing, followed by 37 implementation of differentiated service care models, targeting males. 38

39 Abstract Word Count:286

# 40 **Introduction**:

At the end of 2019, Jamaica had an adult HIV prevalence of 1.5% and an estimated number of 32,000 persons living with HIV (PLHIV)[1]. With regards to the second and third UNAIDS 90-90-90 targets which aim to retain 90% of PLHIV diagnosed on antiretroviral therapy (ART) and ensure that 90% of people receiving ART are virologically suppressed by 2020[2], the country has achieved 44% ART retention and 35% virological suppression[3]. Jamaica is lagging considerably and did not achieve the UNAIDS targets in 2020[4].

47

The Government of Jamaica has provided public access to HIV treatment since 2004[1]. Jamaica also implemented the WHO Treat All strategy in January 2017[5] and a key objective is immediate initiation of ART following HIV diagnosis, regardless of clinical status[6,7]. Despite these efforts to broaden access, a vast majority of PLHIV are still not on treatment[8]. A number of randomized trials have demonstrated multiple benefits of rapid ART initiation compared to later ART start, including improved ART uptake, increased retention in care, higher rates of viral suppression and reduced risk of mortality[9,10].

55

There are several barriers to scale up of viral load (vl) testing in low and middle income countries, such as limited laboratory resources, missed appointments or infrequent measurements[11]. Viral load testing in Jamaica has reportedly been suboptimal due to non-adherence to testing protocols as well as laboratory-based challenges[1]. Viral load testing coverage declined from 53% in December 2019 to 45% in June 2020 [12], three months after COVID-19 protocols, including stay at home orders, were implemented locally. The viral load in patients receiving ART is the best predictor of treatment outcomes[13] but assessing patients with missing test results is also useful

| 63 | to identify appropriate factors that may impede uptake of viral load testing and achieving the |
|----|--|
| 64 | suppression target as well as improve the quality of patient management.                       |

65

The Ministry of Health and Wellness (MoHW) has earmarked the year 2025 for achievement of the 90-90-90 targets[1]. For this to occur, an analysis of factors associated with ART and viral load uptake was recommended in the recent National HIV Strategic Plan. This study aims to describe PLHIV who accessed ART and viral load testing and assess factors associated with uptake of ART and viral load testing.

### 71 Methods:

This secondary analysis uses the National Treatment Service Information System (TSIS2). TSIS2
is a centralized case-based database, governed by the MoHW and currently being used by all HIV
treatment sites in Jamaica. TSIS2 stores patient level demographic and clinical data using over 100
variables.

The MoHW Internal Review Board provided ethical approval (Study No: 2017/20). The dataset
was extracted by the MoHW and fully anonymized before sharing with the study investigator, as
a result patient consent was waived.

### 79 Sample Population

The baseline sample was a total of 8363 PLHIV who initiated HIV treatment between January 2015 and December 2019. For the analytical sample (n=8149), persons in the age group <15 years (n= 215) were excluded because of the small sample size compared to other age categories. To assess viral load testing uptake, the sample included only those eligible within the study period.

84

## 86 Data Analysis

- Descriptive statistics were used to summarise demographic and clinical variables. The categorical
  factors evaluated included age group, gender, location by regional health authority (RHA) and first
  viral load test (vl) status (suppressed or non-suppressed) as defined by the *National Clinical Management of HIV Disease Guidelines*[5]. We assessed two primary outcomes:
  a.) Time to ART initiation based on the difference between the first clinic date and the ART
  initiation date. If these dates were the same, patients were classified as having same-day ART
- 93 initiation. ART initiation time/days is reported using six categories (preclinic, same day, 1-7, 894 21, 22-30 and 31+).
- b.) Time to the first viral load test determined by the duration between the first ART date and the
  first viral load test date. Time to viral load testing/months is reported using four categories
  (baseline or pre-ART, 0-6, 7-12 and 13+).
- Multivariable logistic regression was used to assess factors associated with ART initiation (31+
  days vs. same day initiation) and the uptake of viral load testing (viral load test vs. no viral load
  test). We report adjusted odds ratios and confidence intervals.

### 101 **Results**

### 102 Data summary

103

The analytical sample (Table 1) showed those initiating treatment were more likely to be female (n=4408, 54%), 20-39 years (n=4407, 53%) and located in the South East Region (SERHA (n=4141, 51%). Most were diagnosed at an early HIV stage (n=4430, 60%) and initiated ART at either 31+ days after the first clinic visit (n=3666, 45%) or the same day (n=3463, 43%). The median time to ART initiation was 15 days and most were virally non-suppressed (n=3713, 53%)

at the first viral load test. The first viral load tests were mainly done between 0-6 months (n=3047,

- 110 37%).
- 111

# Table 1. Demographic and clinical characteristics for the analytical sample of PLHIV on HIV treatment, from 2015-2019 in Jamaica (N=8149).

| Variables  |      |     |  |
|--|------|-----|--|
| Levels   | Ν    | %   |  |
| Gender   |      |     |  |
| Female   | 4408 | 54  |  |
| Male   | 3739 | 46  |  |
| Missing  | 2    |     |  |
| Age group at ART initiation/years                    |      |     |  |
| Mean(sd)   | 38(  | 13) |  |
| 15-19  | 400  | 5   |  |
| 20-39  | 4407 | 53  |  |
| 40+  | 3342 | 40  |  |
| Missing  | 51   |     |  |
| Regional Health Authority (RHA)                      |      |     |  |
| South East (SERHA)                                   | 4141 | 51  |  |
| Western (WRHA)                                       | 1875 | 23  |  |
| North East (NERHA)                                   | 1124 | 14  |  |
| Southern (SRHA)                                      | 1009 | 12  |  |
| HIV stage at diagnosis <sup>b</sup>                  |      |     |  |
| early diagnosis                                      | 4430 | 60  |  |
| late diagnosis                                       | 2941 | 40  |  |
| Missing  | 778  |     |  |
| ART initiation time/days <sup>c</sup>                |      |     |  |
| Median time to ART initiation(IQR) 15 (449)          |      |     |  |
| preclinic  | 277  | 4   |  |
| same day   | 3463 | 43  |  |
| 1-7  | 201  | 2   |  |
| 8-21   | 282  | 3   |  |
| 22-30  | 260  | 3   |  |
| 31+  | 3666 | 45  |  |
| Time to first viral load test/months <sup>d</sup>    |      |     |  |
| Median time to first viral load test 0.1(8)<br>(IQR) |      |     |  |

| baseline test (pre-ART)                                 | 2739                | 34                 |  |  |  |  |  |
|---|---------------------|--------------------|--|--|--|--|--|
| 0-6   | 3047                | 37                 |  |  |  |  |  |
| 7-12  | 792                 | 10                 |  |  |  |  |  |
| 13+   | 447                 | 5                  |  |  |  |  |  |
| no viral load test                                      | 1124                | 14                 |  |  |  |  |  |
| Viral load status at first viral load test <sup>e</sup> |                     |                    |  |  |  |  |  |
| Median first viral load result (IOR)                    | 1655(3              | 5662)              |  |  |  |  |  |
|   | 1055(5              | 5005)              |  |  |  |  |  |
| non-suppressed  | 3713                | 53                 |  |  |  |  |  |
| non-suppressed<br>suppressed                            | <u>3713</u><br>3312 | 53663)<br>53<br>47 |  |  |  |  |  |

a) Percentages have been rounded up

- b) Based on baseline CD4 test results: Patients starting ART with CD4 cell count ≥350 cells/mm3
   were characterized as achieving early diagnosis, while CD4 <350 cells/mm3 was defined as late diagnosis.</li>
- 118 c) Time/days to ART initiation is the time from first clinic date to ART initiation.
- d) Time/months to first viral load test is the time from ART initiation to first viral load test
- e) Based on the first viral load test after initiating treatment, followed by categorization according to
- the first viral load test results at that time period (<1000 copies/mL versus  $\geq$ 1000 copies/mL).

### 123 **ART initiation time**

124 Figure 1 shows the proportion of PLHIV with same day ART initiation increased steadily each

- year from 32% in 2015 to 55% in 2019. This represents a 72% increase over 5 years or a 37.5%
- increase since the implementation of the "Treat All" strategy in 2017.

### 127 Fig 1. Proportion of PLHIV in Jamaica with same day ART initiation between 2015-2019.

- 128
- 129 Table 2. shows for persons with same day ART initiation (N= 3461), there was no difference
- between genders or HIV stage of diagnosis. Most persons were 20-39 years old (n=1817, 53%)
- and had achieved viral suppression at the first viral load test (n=1477, 53%). For persons initiating
- ART 31+ days after the first clinic visit (n=3666), most were diagnosed at an early stage (n=2611,
- 133 71%) but were virally non-suppressed (n=1965, 58%) at the first viral load test.

# Table 2. Demographic and clinical characteristics of PLHIV by ART initiation time, for 2015-2019.

| Var                    | iables     | Time to ARV initiation/days <sup>c</sup> |       |       |       |       |       |        |
|------------------------|------------|--|-------|-------|-------|-------|-------|--------|
|                        |            | Preclinic same 1-7 8-21 22-30 31+        |       |       |       |       |       |        |
|                        |            | n  | day   | n     | n     | n     | n     |        |
|                        |            | (%)                                      | n     | (%)   | (%)   | (%)   | (%)   |        |
|                        |            |  | (%)   |       |       |       |       |        |
| Gender                 | Female     | 156                                      | 1733  | 91    | 139   | 128   | 2161  | <0.001 |
|                        |            | (56%)                                    | (50%) | (45%) | (49%) | (49%) | (59%) |        |
|                        | Male       | 121                                      | 1728  | 110   | 143   | 132   | 1505  |        |
|                        |            | (44%)                                    | (50%) | (55%) | (51%) | (51%) | (41%) |        |
|                        | Missing    |  | 2     |       |       |       |       |        |
| Age                    | 15-19      | 21                                       | 226   | 15    | 15    | 17    | 106   | <0.001 |
| group/year             |            | (8%)                                     | (7%)  | (8%)  | (5%)  | (7%)  | (3%)  |        |
| s <sup>b</sup>         |            |  |       |       |       |       |       |        |
|                        | 20-39      | 131                                      | 1817  | 111   | 151   | 123   | 2074  |        |
|                        |            | (47%)                                    | (53%) | (55%) | (54%) | (47%) | (57%) |        |
|                        | 40+        | 125                                      | 1420  | 75    | 116   | 120   | 1486  |        |
|                        |            | (45%)                                    | (40%) | (37%) | (41%) | (46%) | (40%) |        |
| RHA                    | North East | 28                                       | 446   | 58    | 72    | 54    | 466   | <0.001 |
|                        |            | (10%)                                    | (13%) | (29%) | (26%) | (21%) | (13%) |        |
|                        | South East | 133                                      | 1735  | 88    | 128   | 136   | 1921  |        |
|                        |            | (48%)                                    | (50%) | (44%) | (45%) | (52%) | (52%) |        |
|                        | Southern   | 22                                       | 436   | 22    | 23    | 17    | 489   |        |
|                        |            | (8%)                                     | (13%) | (11%) | (8%)  | (7%)  | (13%) |        |
|                        | Western    | 94                                       | 846   | 33    | 59    | 53    | 790   |        |
|                        |            | (34%)                                    | (24%) | (16%) | (21%) | (20%) | (22%) |        |
| HIV stage              | early      | 101                                      | 1418  | 82    | 107   | 111   | 2611  | <0.001 |
| at                     |            | (41%)                                    | (49%) | (46%) | (42%) | (47%) | (71%) |        |
| diagnosis <sup>d</sup> |            |  |       |       |       |       |       |        |
|                        | late       | 146                                      | 1498  | 95    | 146   | 124   | 932   |        |
|                        |            | (59%)                                    | (51%) | (54%) | (58%) | (53%) | (29%) |        |
|                        | Missing    | 30                                       | 547   | 24    | 29    | 25    | 123   |        |
| First viral            | suppressed | 129                                      | 1477  | 82    | 118   | 131   | 1375  | <0.001 |
| load test              |            | (53%)                                    | (53%) | (50%) | (49%) | (56%) | (42%) |        |
| status <sup>e</sup>    |            | . ,                                      | . ,   |       | . ,   | . ,   | . ,   |        |
|                        | non-       | 113                                      | 1329  | 81    | 123   | 102   | 1965  |        |
|                        | suppressed | (47%)                                    | (47%) | (50%) | (51%) | (44%) | (58%) |        |
|                        | Missing    | 35                                       | 657   | 38    | 41    | 27    | 326   |        |

<sup>137</sup> 138

a) Percentages have been rounded up

b) Persons <15 years were excluded because of small sample size

139 c) Time/days to ART initiation is the time from first clinic date to ART initiation.

d) Based on baseline CD4 test results: Patients starting ART with CD4 cell count  $\geq$  350 cells/mm3

were characterized as achieving early diagnosis, while CD4 <350 cells/mm3 was defined as late 141 142 diagnosis. e) Based on the first viral load test after initiating treatment, followed by categorization according to 143 the first viral load test results at that time period (<1000 copies/mL versus  $\geq$ 1000 copies/mL). 144 145 Uptake of viral load testing 146 Figure 2. shows of persons who were eligible for a 1<sup>st</sup> viral load test (n=6836), 90% (n=6146) had 147 148 a test documented and 79% (n=4827) of those had a second viral load test documented. Only 10% (n=690) did not have a first viral load test recorded in TSIS2 despite being eligible to receive 149 testing. Persons were excluded (n=2003) because viral load testing was done before the study 150 period or they were not yet eligible for testing based on the national guidelines. 151 Fig 2. Viral load testing uptake among PLHIV on ART in Jamaica, from 2015-2019. 152 153 Table 3. shows among persons with a first viral load test (n=6146), most were female. 20-39 years 154 old at the time of treatment and diagnosed at early HIV stage. Uptake of vl testing was highest in 155 SERHA and lowest in SRHA. Viral load testing was mostly done after 0-6 months on HIV 156 treatment (n=3034, 44%). However, 28% (n=1878) received a baseline vI test before starting 157

159 first viral load test. Those without a vl test were mostly males, 20-39 years old, diagnosed early

treatment. Those with a baseline viral load test were mostly non-suppressed (n=1442, 77%) at the

and located in SERHA.

# Table 3. Demographic and clinical characteristics for PLHIV on HIV treatment by time to uptake of first viral load test.

163

158

|           |        | Time to first viral load test/months <sup>b</sup> |               |               |              |                  |        |  |
|-----------|--------|---|---------------|---------------|--------------|------------------|--------|--|
| Variables |        | baseline<br>(pre-ART)<br>n (%)                    | 0-6<br>n (%)  | 7-12<br>n (%) | 13+<br>n (%) | no test<br>n (%) | Р      |  |
| Gender    | Female | 1057<br>(56%)                                     | 1591<br>(52%) | 390<br>(49%)  | 217<br>(48%) | 325<br>(47%)     | <0.001 |  |

|                        | Male       | 821 (44%) | 1443     | 398     | 229     | 364      |         |
|------------------------|------------|-----------|----------|---------|---------|----------|---------|
|                        |            |           | (48%)    | (51%)   | (52%)   | (53%)    |         |
|                        | Missing    |           |          |         |         | 1        |         |
| Age                    | 15-19      | 93 (5%)   | 146 (5%) | 38 (5%) | 27 (6%) | 58 (8%)  | <0.001  |
| group/year             |            |           |          |         |         |          |         |
|                        | 20-39      | 1011(54%) | 1619     | 401     | 256     | 403      |         |
|                        |            |           | (53%)    | (51%)   | (57%)   | (58%)    |         |
|                        | 40+        | 774(41%)  | 1269     | 349     | 163     | 229      |         |
|                        |            |           | (42%)    | (44%)   | (37%)   | (34%)    |         |
| RHA                    | North East | 346 (18%) | 399      | 87      | 45      | 72 (10%) | <0.001  |
|                        |            |           | (13%)    | (11%)   | (10%)   |          |         |
|                        | South East | 900 (48%) | 1720     | 337     | 210     | 336(48%) |         |
|                        |            |           | (57%)    | (43%)   | (47%)   |          |         |
|                        | Southern   | 268 (14%) | 302      | 75 (9%) | 34 (8%) | 94 (16%) |         |
|                        |            |           | (10%)    |         |         |          |         |
|                        | Western    | 364 (20%) | 613      | 289     | 157     | 188      |         |
|                        |            |           | (20%)    | (37%)   | (35%)   | (26%)    |         |
| HIV stage              | early      | 1105      | 1527     | 411     | 210     | 271      | <0.001  |
| at                     |            | (61%)     | (54%)    | (55%)   | (49%)   | (64%)    |         |
| diagnosis <sup>c</sup> |            |           |          |         |         |          |         |
|                        | late       | 711 (39%) | 1326     | 334     | 215     | 150      |         |
|                        |            |           | (46%)    | (45%)   | (51%)   | (36%)    |         |
| First viral            | suppressed | 436 (23%) | 1819     | 576     | 226     | NA       | < 0.001 |
| load test              |            |           | (60%)    | (74%)   | (51%)   |          |         |
| status <sup>d</sup>    |            |           |          |         |         |          |         |
|                        | non-       | 1442      | 1215     | 212     | 220     | NA       |         |
|                        | suppressed | (77%)     | (40%)    | (26%)   | (49%)   |          |         |

164 165 a) Percentages have been rounded up

b) Time/months to first viral load test is the time from ART initiation to first viral load test

c) Based on baseline CD4 test results: Patients starting ART with CD4 cell count ≥350 cells/mm3
 were characterized as achieving early diagnosis, while CD4 <350 cells/mm3 was defined as late diagnosis.</li>

d) Based on the first viral load test after initiating treatment, followed by categorization according to the first viral load test results at that time period (<1000 copies/mL versus ≥1000 copies/mL).</li>

## 171 Factors associated with ART initiation and viral load testing uptake

172 In Figure 3, same day ART initiation was significantly more likely for males compared to females

173 (aOR=1.46, CI=1.32-1.62), 15 - 19 years old compared to 20 - 39 years olds and individuals from

174 WRHA compared to the ones from SERHA. Those virally suppressed were also significantly more

175 likely to be initiated on ART the same day compared to those who were non-suppressed176 (aOR=1.58, CI=1.43-1.75).

# Fig 3. Results of the logistic regression analysis to assess association of PLHIV demographic and clinical variables with ART uptake (31+days vs. same day ART initiation)

- 179 Figure 4 shows males were significantly more likely to not have a first viral load test compared to
- 180 females (aOR=1.55, CI=1.27-1.90). Persons in WRHA were also significantly more likely not to
- have a viral load test compared to SERHA (aOR=01.29, CI=1.02-1.61). Persons 40+ years were
- significantly more likely to have a viral load test compared to 20-39 years (aOR=0.73, CI=0.58-
- 183 0.90). Similarly, persons diagnosed at a late HIV stage (aOR=0.70. CI=0.57-0.86) and those
- located in NERHA (aOR=0.66, CI=0.41-0.85) where significantly more likely to have a viral load
- test compared to those diagnosed early and those located in SERHA.

# Fig 4. Results of the logistic regression analysis to assess association of PLHIV demographic and clinical variables with viral load status (viral load test vs. no viral load test)

188

# 189 **Discussion**

Our study shows the current goal of immediate ART initiation is gradually being met, 190 demonstrated by a 72% increase in same day ART initiation over the five-year study period. Those 191 192 initiating treatment were mostly females but males were significantly more likely to have same day initiation. Persons initiating ART later (31+ days after the first clinic visit) were mostly virally 193 non-suppressed while those with same day initiation had achieved viral suppression at the first 194 195 viral load test. This demonstrates the benefit of immediate HIV treatment. However, while immediate treatment initiation is the current goal, it is important to ensure persons are also ready 196 197 to start treatment [5]. Evidence suggests rapid initiation of ART could lead to increased loss to

follow-up because of insufficient time to accept and disclose HIV status and to prepare for lifelongtreatment[7].

Coverage of the first viral load test was 90% among eligible persons but declined to 79% for the 200 201 second test, indicating Jamaica has adapted routine viral load testing but retention is lacking. For 202 viral suppression to occur once on treatment, continuous engagement with care is necessary[14]. WHO estimates on average, between 64% to 94% of people will still be in care one year after 203 starting HIV treatment[15]. Considering the frequency of missing viral load tests, there is need to 204 assess the barriers to retention and conduct routine assessment of patients with missing records to 205 206 provide more robust information for quality improvement and to mitigate possible service delivery challenges. 207

Most persons were virally non-suppressed at first viral load test and had received this test between 208 209 0-6 months after initiating ART, which is consistent with the current national guidelines[5]. 210 Coverage of baseline (pre-ART initiation) viral load testing was 28%, despite the national guidelines stipulating testing after persons have started treatment. Males and persons with late HIV 211 212 diagnosis were significantly more likely to not have a viral load test. Males have demonstrated the tendency to delay in seeking health care[16] and persons with a late diagnosis may also be more 213 likely to delay viral load testing. Jamaica has a decentralized health system but HIV viral load 214 testing is only provided by the national laboratory, which limits access. UNAIDS estimates that 215 globally 95% of HIV service delivery is currently facility based and to optimize efficiencies, it is 216 217 suggested that community-based service delivery be ramped up[17]. In a previous paper[18], we suggest Jamaica explore scaling up viral load testing through decentralizing testing to treatment 218 219 sites, some of which are community based. Research has also demonstrated how differentiated

service delivery (DSD) can be applied to improve uptake in specific populations, such as males[19,20]. Successful DSD implementation aims to simplify and adapt services to patients needs and requires that countries determine the barriers to access as well as specific needs of hardto-reach populations to improve uptake of services[21] and consequently, health outcomes.

We also recommend exploring the effects of supply chain performance on ART and viral load testing uptake. A better understanding of these consumption variables at service delivery points can only serve to improve patient management and bridge the analysis gap. This has become particularly relevant within the context of the COVID-19 pandemic which saw HIV services being diverted or slowed resulting in stock outs and backlogs in viral load testing[22]. It should not be assumed that poor uptake only occurs as a result of a patient's negligence when there may be challenges within the system or supply chain[23].

We recognize the limitations of the data. Improved accuracy is expected if the data was normally 231 distributed[24,25]. A recent data quality audit carried out by the HIV Strategic Information Unit 232 measured the completeness of data in TSIS2 at 63%[12]. Missing data or non-entry of data could 233 be responsible for persons not having a documented viral load test and not necessarily non-uptake 234 235 of testing services. The data did not allow us to measure the time retained on ART, time retained in care or assess virologic failure. We are unable to relate timing of viral load test to clinic 236 attendance or adherence. Table 3. shows 23% of persons were virally suppressed prior to ART 237 initiation, indicating these persons may have been in treatment at clinics not included in the 238 239 government data (or overseas). The data includes patients receiving both private and public care and did not attempt to separate. However, the sample size is large and includes all persons on HIV 240 treatment for the study period, which limits selection bias. According to the c-statistic from the 241

regression analyses, the variables assessed produced strong models with 62% accuracy for viral
load testing uptake and 60% accuracy for ART initiation. Medians are reported to account for
skewness of the data.

245

# 246 Conclusion

The goal of immediate ART initiation is increasingly being met and is significantly associated with viral suppression at the first viral load test. Males were more likely to be initiated on ART the same day as the first clinic visit but less likely to have a viral load test after ART initiation. A qualitative assessment should be conducted to understand important challenges in accessing routine viral load testing, followed by implementation of differentiated care models targeting males.

## 253 Financial Disclosure statement:

254 The author(s) received no specific funding for this work.

255

256

# 257 Acknowledgements:

The authors would like to thank the HIV/STI/TB Strategic Information Unit for providing thebaseline data.

# 260 Acronyms

- 261 ART antiretroviral therapy,
- 262 PLHIV persons living with HIV,
- 263 NERHA Northeast Regional Health Authority,
- 264 RHA- Regional Health Authority,
- 265 SERHA-Southeast Regional Health Authority,
- 266 SRHA Southern Regional Health Authority,
- 267 WRHA Western Regional Health Authority.

## 268 Data Sharing Statement

- 269 The study investigator was required to sign a confidentiality agreement which prevents data
- sharing. Full data can be requested directly from the Ministry of Health and Wellness.

# 272 **References**

- 1. Ministry of Health and Wellness. National HIV Strategic Plan 2020-2025. 2020.
- UNAIDS. 90-90-90: An ambitious treatment target to help end the AIDS epidemic. Joint
   United Nations Programme on HIV/AIDS; 2014 p. 40.
- UNAIDS. Country Factsheet: Jamaica [Internet]. 2019 [cited 2021 Feb 3]. Available from: https://www.unaids.org/en/regionscountries/countries/jamaica
- Figueroa JP, Duncan JP, Bailey A, Skyers N. The HIV epidemic in Jamaica: a need to
   strengthen the National HIV Program. Rev Panam Salud Pública [Internet]. 2020 Nov 20
   [cited 2021 Jan 20];44. Available from:
- 281 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679044/
- Ministry of Health, Jamaica. Clinical Management Of HIV Disease; Guidelines for Medical
   Practitioners. 2017 p. 130.
- WHO. Consolidated guidelines on HIV testing services [Internet]. World Health
   Organization; 2015 [cited 2019 Apr 23]. Available from:
   http://www.unaids.org/sites/default/files/media asset/JC2484 treatment-2015 en 1.pdf
- Information NC for B, Pike USNL of M 8600 R, MD B, Usa 20894. RECOMMENDATION FOR
   RAPID INITIATION OF ART [Internet]. Guidelines for Managing Advanced HIV Disease and
   Rapid Initiation of Antiretroviral Therapy. World Health Organization; 2017 [cited 2021 Feb
   Available from: https://www.ncbi.nlm.nih.gov/books/NBK475972/
- Jamaica Gleaner. Fewer than 50% of people with HIV getting treatment. 2020 Feb 11 [cited
   2021 Feb 3]; Available from: http://jamaica-gleaner.com/article/lead stories/20200211/fewer-50-people-hiv-getting-treatment
- Labhardt ND, Ringera I, Lejone TI, Klimkait T, Muhairwe J, Amstutz A, et al. Effect of Offering
   Same-Day ART vs Usual Health Facility Referral During Home-Based HIV Testing on Linkage
   to Care and Viral Suppression Among Adults With HIV in Lesotho: The CASCADE
   Randomized Clinical Trial. JAMA [Internet]. 2018 Mar 20 [cited 2021 Feb 4];319(11):1103.
- Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2018.1818
- Lilian RR, Rees K, McIntyre JA, Struthers HE, Peters RPH. Same-day antiretroviral therapy
   initiation for HIV-infected adults in South Africa: Analysis of routine data. PLOS ONE
   [Internet]. 2020 Jan 14 [cited 2021 Jan 27];15(1):e0227572. Available from:
- 302 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0227572
- 303 11. Zadrozny, S., Weir, S., Edwards, J., & Herce, M. (2018). Applying new methods to estimate
   304 viral suppression: The "last 90." Chapel Hill, NC, USA: MEASURE Evaluation, University of
   305 North Carolina;

- Ministry of Health and Wellness; HIV Strategic Information Unit. Strategic Information
   Overview: Treatment, Care and Support Annual Review. unpublished report; 2020.
- 13. Awungafac G, Amin ET, Fualefac A, Takah NF, Agyingi LA, Nwobegahay J, et al. Viral load
- 309 testing and the use of test results for clinical decision making for HIV treatment in
- Cameroon: An insight into the clinic-laboratory interface. PLoS ONE [Internet]. 2018 Jun 11
- 311 [cited 2021 Jan 20];13(6). Available from:
- 312 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995384/
- 313 14. WHO. Updated recommendations on HIV prevention, infant diagnosis, antiretroviral
   314 initiation and monitoring: March 2021. Geneva: World Health Organization; 2021. Licence:
   315 CC BY-NC-SA 3.0 IGO. [Internet]. WHO; Available from:
- 316 https://www.who.int/publications/i/item/9789240023581
- The HIV treatment cascade [Internet]. Avert. 2016 [cited 2021 Sep 27]. Available from:
   https://www.avert.org/professionals/hiv-programming/treatment/cascade
- 16. Olanrewaju FO, Ajayi LA, Loromeke E, Olanrewaju A, Allo T, Nwannebuife O. Masculinity
  and men's health-seeking behaviour in Nigerian academia. Amoo EO, editor. Cogent Soc
  Sci [Internet]. 2019 Jan 1 [cited 2021 Sep 27];5(1):1682111. Available from:
  https://doi.org/10.1080/23311886.2019.1682111
- 17. UNAIDS. 2020 Global AIDS Update Seizing the moment Tackling entrenched
   inequalities to end epidemics. 2020;384.
- 18. Cushnie A, Reintjes R, Lehtinen-Jacks S, Figueroa JP. HIV program outcomes for Jamaica
  before and after "Treat All": A population-based study using the national treatment
- 327 services database. PLOS ONE [Internet]. 2021 Aug 12 [cited 2021 Aug 12];16(8):e0255781.
   328 Available from:
- 329 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0255781
- 19. Ehrenkranz P, Grimsrud A, Rabkin M. Differentiated service delivery: navigating the path to
   scale. Curr Opin HIV AIDS. 2019 Jan;14(1):60–5.
- 20. Mukumbang FC. Leaving No Man Behind: How Differentiated Service Delivery Models
- Increase Men's Engagement in HIV Care. Int J Health Policy Manag [Internet]. 2020 Mar 7
- 334 [cited 2021 Dec 16];10(3):129–40. Available from:
- 335 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947905/
- WHO. Updated recommendations on service delivery for the treatment and care of people
   living with HIV. Geneva: World Health Organization; 2021. 2021.
- 22. A tale of two Jamaican clinics during COVID-19 [Internet]. [cited 2021 May 9]. Availablefrom:

- https://www.unaids.org/en/resources/presscentre/featurestories/2020/november/20201
   103\_jamaica
- 342 23. Nyogea DS, Said H, Mwaigomole G, Stoeckle M, Felger I, Hatz C, et al. An assessment of the
  343 supply chain management for HIV/AIDS care and treatment in Kilombero and Ulanga
  344 districts in Tanzania. Tanzan J Health Res [Internet]. 2015 [cited 2021 Mar 5];17(2).
- Available from: https://www.ajol.info/index.php/thrb/article/view/111567
- 24. Austin PC, Steyerberg EW. Interpreting the concordance statistic of a logistic regression
  model: relation to the variance and odds ratio of a continuous explanatory variable. BMC
  Med Res Methodol [Internet]. 2012 Jun 20 [cited 2021 Jan 28];12(1):82. Available from:
  https://doi.org/10.1186/1471-2288-12-82
- 25. Samson OO, Nyandwaki MJ, Mutwiri P, Wandera O, Oriema O, Otumba EO. The application
- of logistic regression in modeling of survival chances of HIV-positive patients under highly
- active antiretroviral therapy (HAART): A Case of Nyakach District, Kenya. In 2014.
- 353



Fig 1-PLHIV with same day ART initiation





Fig 2 - Viral load testing uptake among PLHIV on ART

Fig 3-Results of the logistic regression analysis to assess association of PLHIV demographic and clinical variables with ART uptake (31+days vs. same day ART initiation)



Fig 3-Adjusted odds ratios for ART uptake

Fig 4. Results of the logistic regression analysis to assess association of PLHIV demographic and clinical variables with viral load status (viral load test vs. no viral load test)



Fig 4-Adjusted odds ratios for viral load status